Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

III.c

III - Pulmonary/alveolar./airway hemorrhage/bleeding

Hemoptysis

Last update 17/06/2026

(Fr: hémoptysie isolée). Lone hemoptysis. Hemoptysis presumed to be drug-induced may disclose an underlying airway or pulmonary benign or malignant condition. Hemoptysis is a classic, though inconsistent manifestation of underlying diffuse alveolar hemorrhage or DAH (see under IIIa). Certain drugs do increase the risk of post-procedural (e.g. TBLB, maybe also cryobiopsy) bleeding and need to be withdrawn prior to the procedure

Causative drugs

39

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Alteplase (rTPA)
III.a
III.c
III.k
V.a
V.r
V.an
VI.e
X.f
Amikacin (inhaled-, liposomal-)
I.a
I.e
I.ap
III.c
IV.a
IV.b
V.d
V.e
V.f
V.g
XIX.d
Amiodarone
I.a
I.b
I.c
I.d
I.e
I.f
I.g
I.i
I.l
I.m
I.t
I.v
I.x
I.aa
I.ab
I.ap
I.au
I.ay
I.az
II.e
II.m
III.a
III.c
IV.a
IV.k
IV.ab
V.a
VI.a
VI.c
VI.d
VI.u
VII.a
VII.i
IX.a
IX.d
IX.ai
X.d
X.f
X.s
XI.c
XI.g
XII.a
XII.c
XII.f
XII.n
XII.o
XII.q
XII.v
XII.ah
XII.aw
XV.g
XVI.b
XVI.i
XVI.j
XVI.n
XVI.s
XVI.w
XVI.x
XVI.ab
XVI.ac
XVI.ba
XVI.bb
XVI.bn
XVI.bt
XVI.bv
XVI.cb
XVII.b
XVII.j
XVII.k
XVII.p
XVIII.a
XVIII.b
XVIII.c
XVIII.e
XVIII.f
XVIII.m
XVIII.p
XIX.a
XIX.b
XIX.c
XIX.d
XIX.e
XIX.k
XIX.o
XIX.q
XIX.r
XIX.v
XIX.w
XIX.aa
XIX.ae
XIX.ag
XIX.aj
XIX.ak
XIX.bm
XX.e
Anticoagulants, direct oral (anti-thrombin, -IIa, -Xa) - NOAC
I.a
I.b
II.e
III.a
III.c
III.k
III.m
V.b
VI.e
VI.n
IX.x
X.a
XVI.j
Anticoagulants, oral (vitamin K antagonists-VKA)
I.z
III.a
III.c
III.e
III.k
IV.ah
V.a
V.b
V.r
V.u
V.v
VI.e
VI.n
VIII.g
IX.x
X.a
XI.i
XI.aj
XII.at
XVIII.d
XVIII.e
XXVI.h
Antiplatelet agents: Glycoprotein IIb/IIIa inhibitors
II.g
III.a
III.c
V.r
IX.x
Apatinib
I.a
III.c
III.h
VI.f
Aspirin (Salicylate-ASA) - Aspirin containing drugs
I.b
I.c
I.m
II.a
II.e
III.a
III.c
III.m
IV.a
IV.b
V.a
V.y
VI.e
VIII.b
X.a
X.f
X.j
X.o
X.s
X.w
XI.b
XI.e
XI.ap
XI.au
XII.o
XII.t
XII.ah
XIX.a
XIX.o
XIX.t
Axitinib
I.a
III.c
V.d
VI.f
XI.t
XVI.bh
Bevacizumab
I.a
II.e
III.a
III.c
III.g
III.h
III.k
IV.a
V.m
V.s
V.ab
VI.f
VII.a
VII.b
X.f
X.u
XI.t
XII.a
XII.f
XII.g
XII.h
XII.ak
XII.al
XII.av
XIII.f
XVI.ac
XVI.ad
XVI.bh
Brodifacoum
III.a
III.c
III.m
V.a
V.b
VI.n
VII.a
XXVI.g
XXVI.h
Brodifacoum, inhaled
III.c
III.m
V.b
Butyrfentanyl
III.a
III.c
IX.d
Cannabinoids - Cannabinoid receptor agonists (synthetic) (K2, Spice)
I.b
I.c
I.d
I.ap
II.a
II.e
II.p
III.a
III.c
III.m
V.b
VII.a
VIII.h
IX.d
X.w
X.bb
XI.b
XI.h
XI.o
XI.x
XI.bg
XII.h
XII.n
XII.al
CAR T-cell therapy
I.ap
II.a
II.c
II.e
II.p
III.c
VI.a
VII.a
X.ap
XII.a
XII.c
XII.g
XII.n
XII.o
XII.q
XII.s
XII.u
XII.ah
XII.aj
XII.ak
XII.bd
XII.bv
XII.bw
XX.b
Loading more…